Sanofi Acquires Oral Alzheimer’s Drug VG-3927 for $470MSanofiSanofi acquires Vigil Neuroscience for $470M to gain rights to VG-3927, a promising once-daily oral TREM2 agonist for Alzheimer’s. The deal boosts Sanofi's position in neurodegenerative disease treatment innovation.
BioNTech Invests $1.3B in UK R&D and AI CentersBioNTechBioNTech announces a $1.3 billion investment in the UK to establish R&D hubs in Cambridge and London, create 400+ jobs, and launch an AI center to accelerate drug discovery and personalized therapies.
Merck KGaA Advances Lupus Drug Enpatoran to Phase 3MerckMerck KGaA advances its lupus drug enpatoran into phase 3 after positive phase 2 results in cutaneous lupus, despite setbacks in systemic lupus cohorts. The drug shows strong efficacy and a favorable safety profile.
FDA Panel Supports Darzalex for Early MyelomaDarzalexJohnson & Johnson's Darzalex Faspro gains FDA advisory backing as a potential first treatment for high-risk smoldering multiple myeloma, despite concerns over trial design, patient selection, and long-term efficacy.
BAFF-R CAR-T: CR 100%CAR-TPeproMene Bio's BAFF-R targeted CAR-T therapy PMB-CT01 shows 100% complete response in Phase 1 trials for B-cell lymphomas and leukemia, offering promising, durable results with manageable safety.
Big Pharma -Waiting for the other Shoe to DropBiotechExplore the shifting landscape of big pharma as clinical trial results, patent cliffs, and innovative therapies shape 2025. Discover how giants like Eli Lilly, Pfizer, and Novo Nordisk navigate challenges and opportunities in weight loss, oncology, and vaccines.
From Closure to Bankruptcy: The Biotech Companies of 2024BiotechExplore the fate of biotech companies in 2024, from closures to bankruptcies, driven by failed clinical trials and cash flow crises. Learn about key company collapses and the industry’s uncertain future.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
